Syndax Pharmaceuticals Inc
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Syndax Pharmaceuticals is a biopharmaceutical company developing therapies for cancer, including revumenib, a menin inhibitor for acute leukemias, and axatilimab, a monoclonal antibody for chronic graft-versus-host disease.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Podlesak DennisDirector | Sell | $114K | 8,000at $14.21 | Oct 29, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable SNDX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.